László Hidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
László Hidi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Attila Oláh
Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary
3 shared publications - Balázs Tamás Németh
Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
3 shared publications - Csaba Mátyás
Laboratory of Cardiovascular Physiology and Tissue Injury, National Institutes of Health/NIAAA, Bethesda, MD, USA
3 shared publications - Dalma Kellermayer
Heart and Vascular Center
3 shared publications - Tamás Radovits
Heart and Vascular Center, Department of Experimental Cardiology and Surgical Techniques, Semmelweis University, 1122 Budapest, Hungary
3 shared publications - Béla Merkely
Heart and Vascular Center, Semmelweis University , Budapest
2 shared publications
Latest Publications
- 1 January 2018
- Published by Cardiologia Hungarica in Cardiologia Hungarica
- Vol. 48 (1) , 20-30
A hasonló fokú fiziológiás és patológiás balkamra-hipertrófia különböző in vivo hemodinamikai következményekhez vezet
- 1 January 2018
- Published by Cardiologia Hungarica in Cardiologia Hungarica
- Vol. 48 (1) , 20-30
A hasonló fokú fiziológiás és patológiás balkamra-hipertrófia különböző in vivo hemodinamikai következményekhez vezet
- Open Access
- 31 October 2015
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 14 (1) , 1-13
The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in different heart diseases. In the current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy. Type-1 DM was induced in rats by streptozotocin. Animals were treated either with the sGC activator cinaciguat (10 mg/kg/day) or with placebo orally for 8 weeks. Left ventricular (LV) pressure–volume (P–V) analysis was used to assess cardiac performance. Additionally, gene expression (qRT-PCR) and protein expression analysis (western blot) were performed. Cardiac structure, markers of fibrotic remodelling and DNA damage were examined by histology, immunohistochemistry and TUNEL assay, respectively. DM was associated with deteriorated cGMP signalling in the myocardium (elevated phosphodiesterase-5 expression, lower cGMP-level and impaired PKG activity). Cardiomyocyte hypertrophy, fibrotic remodelling and DNA fragmentation were present in DM that was associated with impaired LV contractility (preload recruitable stroke work (PRSW): 49.5 ± 3.3 vs. 83.0 ± 5.5 mmHg, P < 0.05) and diastolic function (time constant of LV pressure decay (Tau): 17.3 ± 0.8 vs. 10.3 ± 0.3 ms, P < 0.05). Cinaciguat treatment effectively prevented DM related molecular, histological alterations and significantly improved systolic (PRSW: 66.8 ± 3.6 mmHg) and diastolic (Tau: 14.9 ± 0.6 ms) function. Cinaciguat prevented structural, molecular alterations and improved cardiac performance of the diabetic heart. Pharmacological activation of sGC might represent a new therapy approach for diabetic cardiomyopathy.
- 31 October 2015
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 14 (1) , 1-13
Open AccessThe soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in different heart diseases. In the current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy. Type-1 DM was induced in rats by streptozotocin. Animals were treated either with the sGC activator cinaciguat (10 mg/kg/day) or with placebo orally for 8 weeks. Left ventricular (LV) pressure–volume (P–V) analysis was used to assess cardiac performance. Additionally, gene expression (qRT-PCR) and protein expression analysis (western blot) were performed. Cardiac structure, markers of fibrotic remodelling and DNA damage were examined by histology, immunohistochemistry and TUNEL assay, respectively. DM was associated with deteriorated cGMP signalling in the myocardium (elevated phosphodiesterase-5 expression, lower cGMP-level and impaired PKG activity). Cardiomyocyte hypertrophy, fibrotic remodelling and DNA fragmentation were present in DM that was associated with impaired LV contractility (preload recruitable stroke work (PRSW): 49.5 ± 3.3 vs. 83.0 ± 5.5 mmHg, P < 0.05) and diastolic function (time constant of LV pressure decay (Tau): 17.3 ± 0.8 vs. 10.3 ± 0.3 ms, P < 0.05). Cinaciguat treatment effectively prevented DM related molecular, histological alterations and significantly improved systolic (PRSW: 66.8 ± 3.6 mmHg) and diastolic (Tau: 14.9 ± 0.6 ms) function. Cinaciguat prevented structural, molecular alterations and improved cardiac performance of the diabetic heart. Pharmacological activation of sGC might represent a new therapy approach for diabetic cardiomyopathy.
- 22 May 2014
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 9 (5-6) , 245
Pharmacological activation of the souble guanylate cyclase inhibits pressure overload-induced cardiac hypertrophy
- 22 May 2014
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 9 (5-6) , 245
Pharmacological activation of the souble guanylate cyclase inhibits pressure overload-induced cardiac hypertrophy